Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Editorial: Nicotine and SARS-CoV-2: COVID-19 may be a disease of the nicotinic cholinergic system
Konstantinos Farsalinos, Raymond Niaura, Jacques Le Houezec, et al.
Toxicology Reports (2020) Vol. 7, pp. 658-663
Open Access | Times Cited: 251

Showing 1-25 of 251 citing articles:

The association of smoking status with SARS‐CoV‐2 infection, hospitalization and mortality from COVID‐19: a living rapid evidence review with Bayesian meta‐analyses (version 7)
David Simons, Lion Shahab, Jamie Brown, et al.
Addiction (2020) Vol. 116, Iss. 6, pp. 1319-1368
Open Access | Times Cited: 361
Towards effective COVID‑19 vaccines: Updates, perspectives and challenges (Review)
Daniela Călina, Anca Oana Docea, Demetrios Petrakis, et al.
International Journal of Molecular Medicine (2020) Vol. 46, Iss. 1, pp. 3-16
Open Access | Times Cited: 318
Systematic review of the prevalence of current smoking among hospitalized COVID-19 patients in China: could nicotine be a therapeutic option? Reply
Konstantinos Farsalinos, Anastasia Barbouni, Raymond Niaura
Internal and Emergency Medicine (2020) Vol. 16, Iss. 1, pp. 235-236
Open Access | Times Cited: 219
SARS-CoV-2 antibody prevalence in England following the first peak of the pandemic
Helen Ward, Christina Atchison, Matthew Whitaker, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 209
Current smoking, former smoking, and adverse outcome among hospitalized COVID-19 patients: a systematic review and meta-analysis
Konstantinos Farsalinos, Anastasia Barbouni, Konstantinos Poulas, et al.
Therapeutic Advances in Chronic Disease (2020) Vol. 11
Open Access | Times Cited: 172
Progression of COVID‐19 From Urban to Rural Areas in the United States: A Spatiotemporal Analysis of Prevalence Rates
Rajib Paul, Ahmed A. Arif, Oluwaseun Adeyemi, et al.
The Journal of Rural Health (2020) Vol. 36, Iss. 4, pp. 591-601
Open Access | Times Cited: 168
Antibody prevalence for SARS-CoV-2 following the peak of the pandemic in England: REACT2 study in 100,000 adults
Helen Ward, Christina Atchison, Matthew Whitaker, et al.
medRxiv (Cold Spring Harbor Laboratory) (2020)
Open Access | Times Cited: 168
SARS-CoV-2 pathophysiology and its clinical implications: An integrative overview of the pharmacotherapeutic management of COVID-19
Aristides Tsatsakis, Daniela Călina, Luca Falzone, et al.
Food and Chemical Toxicology (2020) Vol. 146, pp. 111769-111769
Open Access | Times Cited: 150
Safety of COVID-19 vaccines administered in the EU: Should we be concerned?
Antonio F. Hernández, Daniela Călina, Konstantinos Poulas, et al.
Toxicology Reports (2021) Vol. 8, pp. 871-879
Open Access | Times Cited: 134
Health behaviour change during the UK COVID‐19 lockdown: Findings from the first wave of the C‐19 health behaviour and well‐being daily tracker study
Felix Naughton, Emma Ward, Mizanur Khondoker, et al.
British Journal of Health Psychology (2021) Vol. 26, Iss. 2, pp. 624-643
Open Access | Times Cited: 125
‘Spikeopathy’: COVID-19 Spike Protein Is Pathogenic, from Both Virus and Vaccine mRNA
Peter Parry, Astrid Lefringhausen, Conny Turni, et al.
Biomedicines (2023) Vol. 11, Iss. 8, pp. 2287-2287
Open Access | Times Cited: 51
Comprehensive analysis of drugs to treat SARS‑CoV‑2 infection: Mechanistic insights into current COVID‑19 therapies (Review)
George Mihai Niţulescu, Horia Păunescu, Sterghios Moschos, et al.
International Journal of Molecular Medicine (2020) Vol. 46, Iss. 2, pp. 467-488
Open Access | Times Cited: 133
The Effect of Smoking on COVID-19 Symptom Severity: Systematic Review and Meta-Analysis
Aşkın Gülşen, Burcu Arpınar Yiğitbaş, Berat Uslu, et al.
Pulmonary Medicine (2020) Vol. 2020, pp. 1-11
Open Access | Times Cited: 130
Potential Novel Role of COVID-19 in Alzheimer’s Disease and Preventative Mitigation Strategies
Sean X. Naughton, Urdhva Raval, Giulio Maria Pasinetti
Journal of Alzheimer s Disease (2020) Vol. 76, Iss. 1, pp. 21-25
Open Access | Times Cited: 126
Unraveling the Possible Routes of SARS-COV-2 Invasion into the Central Nervous System
Maria Lima, Vasileios Siokas, Athina‐Maria Aloizou, et al.
Current Treatment Options in Neurology (2020) Vol. 22, Iss. 11
Open Access | Times Cited: 115
Interpretable artificial intelligence framework for COVID‑19 screening on chest X‑rays
Nikos Tsiknakis, Eleftherios Trivizakis, Evangelia E. Vassalou, et al.
Experimental and Therapeutic Medicine (2020) Vol. 20, Iss. 2, pp. 727-735
Open Access | Times Cited: 112
Neurobiochemical Cross-talk Between COVID-19 and Alzheimer’s Disease
Mohammad Azizur Rahman, Kamrul Islam, Saidur Rahman, et al.
Molecular Neurobiology (2020) Vol. 58, Iss. 3, pp. 1017-1023
Open Access | Times Cited: 109
Chronic Inflammation in the Context of Everyday Life: Dietary Changes as Mitigating Factors
Denisa Margină, Anca Ungurianu, Carmen Purdel, et al.
International Journal of Environmental Research and Public Health (2020) Vol. 17, Iss. 11, pp. 4135-4135
Open Access | Times Cited: 106
COVID-19, smoking and inequalities: a study of 53 002 adults in the UK
Sarah E. Jackson, Jamie Brown, Lion Shahab, et al.
Tobacco Control (2020) Vol. 30, Iss. e2, pp. e111-e121
Open Access | Times Cited: 104
Smoking and COVID-19: Adding Fuel to the Flame
Vivek K. Kashyap, Anupam Dhasmana, Andrew E. Massey, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 18, pp. 6581-6581
Open Access | Times Cited: 101
Reactive oxygen species as an initiator of toxic innate immune responses in retort to SARS-CoV-2 in an ageing population, consider N-acetylcysteine as early therapeutic intervention
Aikaterini Nasi, Stéphanie McArdle, Gustav Gaudernack, et al.
Toxicology Reports (2020) Vol. 7, pp. 768-771
Open Access | Times Cited: 95
Nicotinic Cholinergic System and COVID-19: In Silico Identification of an Interaction between SARS-CoV-2 and Nicotinic Receptors with Potential Therapeutic Targeting Implications
Konstantinos Farsalinos, Elias Eliopoulos, D.D. Leonidas, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 16, pp. 5807-5807
Open Access | Times Cited: 92
Calming the Storm: Natural Immunosuppressants as Adjuvants to Target the Cytokine Storm in COVID-19
Angela E. Peter, B. V. Sandeep, B. Ganga Rao, et al.
Frontiers in Pharmacology (2021) Vol. 11
Open Access | Times Cited: 84
Toxic metal exposure as a possible risk factor for COVID-19 and other respiratory infectious diseases
Anatoly V. Skalny, Thania Rios Rossi Lima, Tao Ke, et al.
Food and Chemical Toxicology (2020) Vol. 146, pp. 111809-111809
Open Access | Times Cited: 81
COVID‐19, smoking, vaping and quitting: a representative population survey in England
Harry Tattan‐Birch, Olga Perski, Sarah E. Jackson, et al.
Addiction (2020) Vol. 116, Iss. 5, pp. 1186-1195
Open Access | Times Cited: 79
Page 1 - Next Page

Scroll to top